NCT05293717

Topical Ruxolitinib in Chronic Hand Dermatitis

Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD). The study will be conducted at the University of Rochester Medical center, Dermatology Department - Rochester, NY. Qualified and enrolled subjects (see Inclusion/Exclusion criteria) will be required to come to URMC Dermatology Clinic for at least five visits.

Detailed description

This is a single-center study anticipating to enroll 15 participants with chronic hand dermatitis. Eligible participants will receive Ruxolitinib to apply twice daily for 12 weeks. Participants will be required to be seen every 4 weeks until week 16.

Conditions

• Chronic Hand Dermatitis

Interventions

Type	Name	Description
DRUG	Ruxolitinib	1.5% Ruxolitinib cream

Timeline

• Start date: 2022-07-11
• Primary completion: 2023-06-21
• Completion: 2024-12-31
• First posted: 2022-03-24
• Last updated: 2025-02-25
• Results posted: 2024-10-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study